(-0.41%) 5 460.48 points
(-0.12%) 39 119 points
(-0.71%) 17 733 points
(-0.34%) $81.46
(-3.13%) $2.60
(0.01%) $2 336.90
(0.61%) $29.44
(0.28%) $1 009.00
(-0.06%) $0.933
(0.45%) $10.68
(-0.05%) $0.791
(0.86%) $85.73
Live Chart Being Loaded With Signals
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally...
Stats | |
---|---|
Šios dienos apimtis | 414 362 |
Vidutinė apimtis | 160 411 |
Rinkos kapitalizacija | 587.11M |
EPS | $-0.450 ( Q1 | 2024-05-03 ) |
Kita pelno data | ( $-0.310 ) 2024-08-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-3.53 (Sector) 42.63 (Industry) 0 |
ATR14 | $0.0220 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-01 | Xie Jian | Sell | 1 075 | Common Stock |
2024-06-01 | Xie Jian | Sell | 404 | Common Stock |
2024-06-01 | Kim Paul | Sell | 1 129 | Common Stock |
2024-06-01 | Kim Paul | Sell | 424 | Common Stock |
2024-06-01 | Gao Hanlin | Sell | 714 | Common Stock |
INSIDER POWER |
---|
1.63 |
Last 99 transactions |
Buy: 1 993 804 | Sell: 1 954 988 |
Tūris Koreliacija
Fulgent Genetics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
TBLT | 0.958 |
ASLE | 0.957 |
RIVN | 0.957 |
WW | 0.953 |
AGRX | 0.95 |
SSTI | 0.947 |
EBTC | 0.947 |
ESCA | 0.945 |
APPS | 0.945 |
NVTS | 0.944 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
DXJS | -0.942 |
ESTA | -0.942 |
CINF | -0.933 |
ADTH | -0.927 |
CDRO | -0.926 |
KINS | -0.925 |
FLXS | -0.922 |
JSPR | -0.921 |
EWJV | -0.92 |
KBWP | -0.92 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Fulgent Genetics Inc Koreliacija - Valiuta/Žaliavos
Fulgent Genetics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $289.21M |
Bruto pelnas: | $96.61M (33.40 %) |
EPS: | $-5.63 |
FY | 2023 |
Pajamos: | $289.21M |
Bruto pelnas: | $96.61M (33.40 %) |
EPS: | $-5.63 |
FY | 2022 |
Pajamos: | $618.97M |
Bruto pelnas: | $366.90M (59.28 %) |
EPS: | $4.76 |
FY | 2021 |
Pajamos: | $992.58M |
Bruto pelnas: | $777.05M (78.29 %) |
EPS: | $17.25 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Fulgent Genetics Inc
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.